Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Lawitz, Eric, Prof, Sulkowski, Mark S, Prof, Ghalib, Reem, MD, Rodriguez-Torres, Maribel, MD, Younossi, Zobair M, Prof, Corregidor, Ana, MD, DeJesus, Edwin, MD, Pearlman, Brian, Prof, Rabinovitz, Mordechai, Prof, Gitlin, Norman, MD, Lim, Joseph K, MD, Pockros, Paul J, MD, Scott, John D, MD, Fevery, Bart, MSc, Lambrecht, Tom, MSc, Ouwerkerk-Mahadevan, Sivi, PhD, Callewaert, Katleen, MSc, Symonds, William T, PharmD, Picchio, Gaston, PhD, Lindsay, Karen L, MD, Beumont, Maria, MD, Jacobson, Ira M, Prof
Published in The Lancet (British edition) (15.11.2014)
Published in The Lancet (British edition) (15.11.2014)
Get full text
Journal Article
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Sax, Paul E, Dr Prof, Wohl, David, MD, Yin, Michael T, Prof, Post, Frank, MD, DeJesus, Edwin, MD, Saag, Michael, MD, Pozniak, Anton, MD, Thompson, Melanie, MD, Podzamczer, Daniel, MD, Molina, Jean Michel, Prof, Oka, Shinichi, MD, Koenig, Ellen, MD, Trottier, Benoit, MD, Andrade-Villanueva, Jaime, MD, Crofoot, Gordon, MD, Custodio, Joseph M, PharmD, Plummer, Andrew, MS, Zhong, Lijie, PhD, Cao, Huyen, MD, Martin, Hal, MD, Callebaut, Christian, PhD, Cheng, Andrew K, MD, Fordyce, Marshall W, MD, McCallister, Scott, MD
Published in The Lancet (British edition) (27.06.2015)
Published in The Lancet (British edition) (27.06.2015)
Get full text
Journal Article
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Sax, Paul E, Dr, DeJesus, Edwin, MD, Mills, Anthony, MD, Zolopa, Andrew, Prof, Cohen, Calvin, MD, Wohl, David, MD, Gallant, Joel E, Prof, Liu, Hui C, PhD, Zhong, Lijie, PhD, Yale, Kitty, BA, White, Kirsten, PhD, Kearney, Brian P, Pharm D, Szwarcberg, Javier, MD, Quirk, Erin, MD, Cheng, Andrew K, MD
Published in The Lancet (British edition) (30.06.2012)
Published in The Lancet (British edition) (30.06.2012)
Get full text
Journal Article
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Sulkowski, Mark, Dr Prof, Hezode, Christophe, Prof, Gerstoft, Jan, Prof, Vierling, John M, Prof, Mallolas, Josep, MD PhD, Pol, Stanislas, Prof, Kugelmas, Marcelo, MD, Murillo, Abel, MD, Weis, Nina, PhD, Nahass, Ronald, Prof, Shibolet, Oren, MD, Serfaty, Lawrence, MD, Bourliere, Marc, MD, DeJesus, Edwin, MD, Zuckerman, Eli, Prof, Dutko, Frank, PhD, Shaughnessy, Melissa, MS, Hwang, Peggy, PhD, Howe, Anita Y M, PhD, Wahl, Janice, MD, Robertson, Michael, MD, Barr, Eliav, MD, Haber, Barbara, MD
Published in The Lancet (British edition) (21.03.2015)
Published in The Lancet (British edition) (21.03.2015)
Get full text
Journal Article
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Mills, Anthony, MD, Arribas, Jose R, MD, Andrade-Villanueva, Jaime, Prof, DiPerri, Giovanni, MD, Van Lunzen, Jan, Prof, Koenig, Ellen, MD, Elion, Richard, MD, Cavassini, Matthias, MD, Madruga, Jose Valdez, MD, Brunetta, Jason, MD, Shamblaw, David, MD, DeJesus, Edwin, MD, Orkin, Chloe, MBBch, Wohl, David A, MD, Brar, Indira, MD, Stephens, Jeffrey L, MD, Girard, Pierre-Marie, Prof, Huhn, Gregory, MD, Plummer, Andrew, BS, Liu, Ya-Pei, PhD, Cheng, Andrew K, MD, McCallister, Scott, Dr
Published in The Lancet infectious diseases (01.01.2016)
Published in The Lancet infectious diseases (01.01.2016)
Get full text
Journal Article
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Lawitz, Eric, Prof, Lalezari, Jay P, MD, Hassanein, Tarek, Prof, Kowdley, Kris V, Prof, Poordad, Fred F, Prof, Sheikh, Aasim M, MBBS, Afdhal, Nezam H, Prof, Bernstein, David E, Prof, DeJesus, Edwin, MD, Freilich, Bradley, MD, Nelson, David R, Prof, Dieterich, Douglas T, Prof, Jacobson, Ira M, Prof, Jensen, Donald, Prof, Abrams, Gary A, MD, Darling, Jama M, MD, Rodriguez-Torres, Maribel, MD, Reddy, K Rajender, Prof, Sulkowski, Mark S, Prof, Bzowej, Natalie H, MD, Hyland, Robert H, DPhil, Mo, Hongmei, PhD, Lin, Ming, PhD, Mader, Michael, MS, Hindes, Robert, MD, Albanis, Efsevia, MD, Symonds, William T, PharmD, Berrey, Michelle M, MD, Muir, Andrew, Prof
Published in The Lancet infectious diseases (01.05.2013)
Published in The Lancet infectious diseases (01.05.2013)
Get full text
Journal Article
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Lennox, Jeffrey L, Prof, DeJesus, Edwin, MD, Lazzarin, Adriano, Prof, Pollard, Richard B, Prof, Madruga, Jose Valdez Ramalho, MD, Berger, Daniel S, MD, Zhao, Jing, PhD, Xu, Xia, PhD, Williams-Diaz, Angela, BS, Rodgers, Anthony J, MS, Barnard, Richard JO, PhD, Miller, Michael D, PhD, DiNubile, Mark J, MD, Nguyen, Bach-Yen, MD, Leavitt, Randi, MD, Sklar, Peter, Dr
Published in The Lancet (British edition) (05.09.2009)
Published in The Lancet (British edition) (05.09.2009)
Get full text
Journal Article
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Eron, Joseph J, Prof, Young, Benjamin, MD, Cooper, David A, Prof, Youle, Michael, MD, DeJesus, Edwin, MD, Andrade-Villanueva, Jaime, MD, Workman, Cassy, MD, Zajdenverg, Roberto, MD, Fätkenheuer, Gerd, Prof, Berger, Daniel S, MD, Kumar, Princy N, MD, Rodgers, Anthony J, MS, Shaughnessy, Melissa A, MS, Walker, Monica L, BS, Barnard, Richard JO, PhD, Miller, Michael D, PhD, DiNubile, Mark J, MD, Nguyen, Bach-Yen, MD, Leavitt, Randi, MD, Xu, Xia, PhD, Sklar, Peter, Dr
Published in The Lancet (British edition) (01.01.2010)
Published in The Lancet (British edition) (01.01.2010)
Get full text
Journal Article
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
Gallant, Joel E, Daar, Eric S, Raffi, François, Brinson, Cynthia, Ruane, Peter, DeJesus, Edwin, Johnson, Margaret, Clumeck, Nathan, Osiyemi, Olayemi, Ward, Doug, Morales-Ramirez, Javier, Yan, Mingjin, Abram, Michael E, Plummer, Andrew, Cheng, Andrew K, Rhee, Martin S
Published in The lancet HIV (01.04.2016)
Published in The lancet HIV (01.04.2016)
Get more information
Journal Article
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
Sax, Paul E, DeJesus, Edwin, Crofoot, Gordon, Ward, Douglas, Benson, Paul, Dretler, Robin, Mills, Anthony, Brinson, Cynthia, Peloquin, Julie, Wei, Xuelian, White, Kirsten, Cheng, Andrew, Martin, Hal, Quirk, Erin
Published in The lancet HIV (01.04.2017)
Published in The lancet HIV (01.04.2017)
Get more information
Journal Article
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Orkin, Chloe, DeJesus, Edwin, Ramgopal, Moti, Crofoot, Gordon, Ruane, Peter, LaMarca, Anthony, Mills, Anthony, Vandercam, Bernard, de Wet, Joseph, Rockstroh, Jürgen, Lazzarin, Adriano, Rijnders, Bart, Podzamczer, Daniel, Thalme, Anders, Stoeckle, Marcel, Porter, Danielle, Liu, Hui C, Cheng, Andrew, Quirk, Erin, SenGupta, Devi, Cao, Huyen
Published in The lancet HIV (01.05.2017)
Published in The lancet HIV (01.05.2017)
Get more information
Journal Article
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
DeJesus, Edwin, Ramgopal, Moti, Crofoot, Gordon, Ruane, Peter, LaMarca, Anthony, Mills, Anthony, Martorell, Claudia T, de Wet, Joseph, Stellbrink, Hans-Jürgen, Molina, Jean-Michel, Post, Frank A, Valero, Ignacio Pérez, Porter, Danielle, Liu, YaPei, Cheng, Andrew, Quirk, Erin, SenGupta, Devi, Cao, Huyen
Published in The lancet HIV (01.05.2017)
Published in The lancet HIV (01.05.2017)
Get more information
Journal Article